Loading...
•
Dec 31, 2021
Myriad Genetics Q4 2021 Earnings Report
Reported fourth quarter results with revenue of $160.8 million and GAAP EPS of $(0.10).
Key Takeaways
Myriad Genetics reported a 4% increase in revenue to $160.8 million in the fourth quarter of 2021. Diluted GAAP EPS was $(0.10) and adjusted EPS was $(0.02). The company ended the quarter with $398.8 million in cash, cash equivalents and investments.
Revenue of $160.8 million in the fourth quarter, up 4% year-over-year.
Excluding revenue from divested businesses, revenue increased 19% for the fourth quarter.
Diluted GAAP EPS of $(0.10) and adjusted EPS of $(0.02) in the fourth quarter.
Ended the quarter with $398.8 million in cash, cash equivalents and investments.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Myriad Genetics provided financial guidance for fiscal year 2022, expecting revenue between $670 million and $700 million, GAAP EPS between $(0.90) and $(0.70), and adjusted EPS between $0.00 and $0.20.
Positive Outlook
- New product launches
- Tech-enabled commercial capabilities
- Customer-centric tools
- Operational improvements providing a strong foundation for continued growth and innovation
Challenges Ahead
- Uncertainties associated with COVID-19
- Possible effects on the company’s operations and the demand for its products and services
- Risks related to the company’s ability to efficiently and flexibly manage its business amid uncertainties associated with COVID-19
- Risk that sales and profit margins of the company’s existing molecular diagnostic tests may decline or that the company may not be able to operate its business on a profitable basis
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...